Document Detail


Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity.
MedLine Citation:
PMID:  20150556     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To examine the association between liver fat content and very low-density lipoprotein (VLDL)-apolipoprotein (apo) B-100 kinetics and the corresponding responses to weight loss in obese subjects. METHODS AND RESULTS: VLDL-apoB-100 kinetics were assessed using stable isotope tracers, and the fat content of the liver and abdomen was determined by magnetic resonance techniques in 25 obese subjects. In univariate analysis, liver fat content was significantly (P<0.05 in all) associated with body mass index (r=0.65), visceral fat area (r=0.45), triglycerides (r=0.40), homeostasis model assessment score (r=0.40), VLDL-apoB-100 concentrations (r=0.44), and secretion rate (r=0.45). However, liver fat content was not associated with plasma concentrations of retinol-binding protein 4, fetuin A, adiponectin, interleukin-6, and tumor necrosis factor-alpha. Of these 25 subjects, 9 diagnosed as having nonalcoholic fatty liver disease (which is highly prevalent in obese individuals and strongly associated with dyslipidemia) underwent a weight loss program. The low-fat diet achieved significant reduction in body weight, body mass index, liver fat, visceral and subcutaneous fat areas, homeostasis model assessment score, triglycerides, VLDL-apoB-100 concentrations, and VLDL-apoB-100 secretion rate. The percentage reduction of liver fat with weight loss was significantly associated with the corresponding decreases in VLDL-apoB-100 secretion (r=0.67) and visceral fat (r=0.84). CONCLUSION: In patients with obesity, hepatic steatosis increases VLDL-apoB-100 secretion. Weight loss can help reduce this abnormality.
Authors:
Dick C Chan; Gerald F Watts; SengKhee Gan; Annette T Y Wong; Esther M M Ooi; P Hugh R Barrett
Related Documents :
9463536 - Effects of chronic di(2-ethylhexyl) phthalate intake on the secretion and removal rate ...
3887526 - Lipid transport systems: some recent aspects in swine, cattle and trout during developm...
16364276 - Postprandial lipemic response and lipoprotein composition in subjects with low or high ...
11300866 - A novel series of highly potent benzimidazole-based microsomal triglyceride transfer pr...
2896376 - Diet composition and the plasma levels of some peptides regulating pancreatic secretion...
8438776 - A 1-y trial of the effect of high-selenium bread on selenium concentrations in blood an...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-11
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  30     ISSN:  1524-4636     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-15     Completed Date:  2010-05-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1043-50     Citation Subset:  IM    
Affiliation:
Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adiposity
Adult
Aged
Apolipoprotein B-100 / blood*,  secretion
Body Mass Index
Diet, Fat-Restricted
Energy Intake
Fatty Liver / etiology*,  metabolism,  physiopathology
Female
Humans
Kinetics
Lipoproteins, VLDL / blood*,  secretion
Liver / metabolism*,  secretion
Magnetic Resonance Imaging
Male
Middle Aged
Obesity, Abdominal / complications*,  diet therapy,  metabolism,  physiopathology
Treatment Outcome
Triglycerides / blood
Weight Loss
Chemical
Reg. No./Substance:
0/Apolipoprotein B-100; 0/Lipoproteins, VLDL; 0/Triglycerides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TRAIL Promotes VSMC Proliferation and Neointima Formation in a FGF-2-, Sp1 Phosphorylation-, and NF{...
Next Document:  Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation.